ABSTRACT
H.U. Blaser1, R. Gamboni2, B. Pugin1, G. Rihs1, G. Sedelmeier2, B. Schaub2, E. Schmidt2, B. Schmitz2, F. Spindler1 and Hj. Wetter2
Scientific Services a nd2Chemical and Analytical Development Pharma, Novartis AG, CH-4002 Basel, Switzerland
Keywords: Chiral building block, enantioselective hydrogenation, f^-epichlorohydrin,
(7^-levoprotiline, ligand synthesis, process evaluation.
